Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases. The company operates through a network of subsidiaries and commercial infrastructure centered in Greater China, with manufacturing and development activities in Suzhou, China.
−46,6 %
58,6 %
−38,1 %
+15,3 %
2.45
2.27
| % | |
|---|---|
| Oncology products | 65% Cancer therapies including ZEJULA, QINLOCK, OPTUNE, and AUGTYRO. |
| Immunology products | 20% Autoimmune and neuromuscular therapies including VYVGART and VYVGART Hytrulo. |
| Infectious disease products | 12% Anti-infective therapy including NUZYRA and XACDURO. |
| Other commercial and patient-program products | 3% Pre-commercial or other product sales and collaboration-related revenue. |
Zai Lab sells primarily to third-party distributors, who then supply healthcare providers and hospitals, mainly in...
Buy finished products for resale into hospital and retail channels; they are the direct customers and manage inventory and distribution.
End users of the therapies, especially major medical centers across Greater China that drive uptake of specialty medicines.
Oncologists, neurologists, immunologists, and infectious disease physicians who prescribe the products.
Patients whose access depends on NRDL inclusion, supplemental insurance, or hospital coverage.
The business is centered in Greater China, especially mainland China, where most product revenue is generated and where...
Zai Lab’s strategy is to expand patient access to its commercial products while advancing a pipeline across oncology,...
Broader reimbursement and hospital coverage drive prescription volume in China’s specialty-drug market.
New approvals and label expansions can extend product life cycles and diversify revenue.
Licensing and collaboration agreements provide access to external assets and commercialization rights.
Zai Lab faces regulatory, geopolitical, and execution risks tied to operating a China-centered biopharmaceutical...
A limited number of distributors account for a meaningful share of product revenue, so loss of a major customer could reduce sales quickly.
The company is U.S.-listed but operates primarily in mainland China, exposing it to policy, capital-flow, and compliance constraints.
Biopharma operations require compliance with drug, cybersecurity, personal information, and human genetic resource rules.
Sales depend on hospital access, NRDL inclusion, and supplemental insurance coverage.
The company relies on internal and third-party manufacturing for commercial and clinical supply.
Sensitive clinical, commercial, and personal data move through vendors and cloud systems.
: 29.4.2026